跳转至内容
Merck
CN

P-075

Supelco

普里米酮

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C12H14N2O2
化学文摘社编号:
分子量:
218.25
EC 号:
UNSPSC代码:
41116107
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

certified reference material

质量水平

表单

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

1.0 mg/mL in methanol

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

forensics and toxicology

包装形式

single component solution

储存温度

−20°C

SMILES字符串

CCC1(C(=O)NCNC1=O)c2ccccc2

InChI

1S/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16)

InChI key

DQMZLTXERSFNPB-UHFFFAOYSA-N

一般描述

Primidone, marketed as the barbiturate Mysoline®, Prysoline, or Liskantin®, is an anticonvulsant used in the treatment of partial and generalized seizures. This Certified Spiking Solution® is suitable for use in LC/MS or GC/MS applications in clinical toxicology or therapeutic drug monitoring to ensure patients remain within the drug′s therapeutic range.

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Liskantin is a registered trademark of Desitin Arzneimittel GmbH
Mysoline is a registered trademark of Valeant Pharmaceuticals North America LLC
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

警示用语:

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

靶器官

Eyes,Central nervous system

储存分类代码

3 - Flammable liquids

WGK

WGK 2

闪点(°F)

49.5 °F - closed cup

闪点(°C)

9.7 °C - closed cup

法规信息

危险化学品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Günther Deuschl et al.
The Lancet. Neurology, 10(2), 148-161 (2011-01-25)
Essential tremor is a common movement disorder. Tremor severity and handicap vary widely, but most patients with essential tremor do not receive a diagnosis and hence are never treated. Furthermore, many patients abandon treatment because of side-effects or poor efficacy.
Joan Oppenheimer et al.
Water research, 45(13), 4019-4027 (2011-06-15)
Urban watersheds are susceptible to numerous pollutant sources and the identification of source-specific indicators can provide a beneficial tool in the identification and control of input loads, often times needed for a water body to achieve designated beneficial uses. Differentiation
Bradley N Gaynes et al.
Psychiatric services (Washington, D.C.), 60(11), 1439-1445 (2009-11-03)
The authors provide an overview of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (www.star-d.org), a large-scale practical clinical trial to determine which of several treatments are the most effective "next-steps" for patients with major depressive disorder whose symptoms
Nancy L Diaz et al.
Parkinsonism & related disorders, 16(9), 604-607 (2010-08-10)
Although small treatment trials have examined the efficacy of front-line medications in tremor reduction in essential tremor (ET), an overall survey of pharmacological management has not been undertaken in a large sample of ET cases. To conduct a survey of
Susheela Rani et al.
Journal of separation science, 35(3), 359-366 (2012-01-20)
A method for the simultaneous determination of the antiepileptic drugs, phenobarbital (PHB), phenytoin (PTN), carbamazepine (CBZ), primidone (PRM) and oxcarbazepine (OXC) in human plasma and urine samples by using micro-extraction in a packed syringe as the sample preparation method connected

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持